{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:08:17Z","timestamp":1780304897069,"version":"3.54.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470224,82270165,82300242"],"award-info":[{"award-number":["82470224,82270165,82300242"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20221235"],"award-info":[{"award-number":["BK20221235"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002949","name":"Government of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.transproceed.2025.08.014","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T03:59:46Z","timestamp":1757822386000},"page":"1581-1588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Application of Personalized Conditioning Regimens in Relapsed\/Refractory Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"57","author":[{"given":"Shuangzhu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongsheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Li","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.transproceed.2025.08.014_bib0001","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"4","key":"10.1016\/j.transproceed.2025.08.014_bib0002","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1703373","article-title":"Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia","volume":"29","author":"Singhal","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.transproceed.2025.08.014_bib0003","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.bmt.1702690","article-title":"Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM)","volume":"26","author":"Michallet","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.transproceed.2025.08.014_bib0004","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/sj.bmt.1704938","article-title":"Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Kebriaei","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.transproceed.2025.08.014_bib0005","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.transproceed.2025.08.014_bib0006","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ajh.26800","article-title":"Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial","volume":"98","author":"Liu","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.transproceed.2025.08.014_bib0007","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.transproceed.2025.08.014_bib0008","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.transproceed.2025.08.014_bib0009","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.transproceed.2025.08.014_bib0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transproceed.2025.08.014_bib0011","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-014-0059-3","article-title":"Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)","volume":"7","author":"Lai","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.transproceed.2025.08.014_bib0012","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.2009.25.1066","article-title":"Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study","volume":"28","author":"Walter","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.transproceed.2025.08.014_bib0013","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/sj.bmt.1702679","article-title":"Aspergillus tracheobronchitis after allogeneic bone marrow transplantation","volume":"26","author":"van Assen","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.transproceed.2025.08.014_bib0014","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41408-024-01116-5","article-title":"Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial","volume":"14","author":"Cavallaro","year":"2024","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.transproceed.2025.08.014_bib0015","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1089\/scd.2014.0123","article-title":"Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis","volume":"23","author":"Abdul Wahid","year":"2014","journal-title":"Stem Cells Dev"},{"issue":"1","key":"10.1016\/j.transproceed.2025.08.014_bib0016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.1995.13.1.11","article-title":"Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial","volume":"13","author":"Archimbaud","year":"1995","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.transproceed.2025.08.014_bib0017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-024-00982-3","article-title":"Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed\/refractory acute myeloid leukemia: results of a pilot study","volume":"14","author":"Li","year":"2024","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.transproceed.2025.08.014_bib0018","doi-asserted-by":"crossref","first-page":"e0228","DOI":"10.1097\/MD.0000000000010228","article-title":"A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.transproceed.2025.08.014_bib0019","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00277-018-3453-z","article-title":"Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia","volume":"97","author":"Xiao","year":"2018","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.transproceed.2025.08.014_bib0020","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.transproceed.2025.08.014_bib0021","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.24823","volume":"92","author":"Eder","year":"2017","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.transproceed.2025.08.014_bib0022","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.transproceed.2025.08.014_bib0023","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1200\/JCO.22.00491","article-title":"Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study","volume":"40","author":"Houillier","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.transproceed.2025.08.014_bib0024","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bbmt.2019.05.014","article-title":"Thiotepa, fludarabine, and busulfan conditioning regimen before T cell-replete haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia: a bicentric experience of 100 patients","volume":"25","author":"Pagliardini","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.transproceed.2025.08.014_bib0025","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2019.12.725","article-title":"Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with busulfan and fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): a retrospective study","volume":"26","author":"Sora","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"10.1016\/j.transproceed.2025.08.014_bib0026","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2012-03-417998","article-title":"A novel conditioning regimen improves outcomes in beta-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation","volume":"120","author":"Li","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.transproceed.2025.08.014_bib0027","article-title":"Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)","volume":"12","author":"Song","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.transproceed.2025.08.014_bib0028","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1007\/s00277-024-05853-2","article-title":"Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT","volume":"103","author":"Guo","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transproceed.2025.08.014_bib0029","article-title":"Maintenance therapy with chidamide plus azacitidine after allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia patients","volume":"4991","author":"Xiaohui Hu","year":"2023","journal-title":"ASH"},{"issue":"13","key":"10.1016\/j.transproceed.2025.08.014_bib0030","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.transproceed.2025.08.014_bib0031","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2025.08.014_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-024-02382-9","article-title":"Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia","author":"Wang","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.transproceed.2025.08.014_bib0033","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-022-00677-7","article-title":"Clinical outcomes in patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib","volume":"12","author":"Perl","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.transproceed.2025.08.014_bib0034","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/OTT.S336715","article-title":"Rapid and efficient response to gilteritinib and venetoclax-based therapy in two AML patients with FLT3-ITD mutation unresponsive to venetoclax plus azacitidine","volume":"15","author":"Zhang","year":"2022","journal-title":"Onco Targets Ther"},{"issue":"24","key":"10.1016\/j.transproceed.2025.08.014_bib0035","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525004312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525004312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:36:25Z","timestamp":1780302985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134525004312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0041134525004312"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.08.014","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Application of Personalized Conditioning Regimens in Relapsed\/Refractory Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}